The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | The potential applications for immunotherapy in MPNs
Tania Jain, MBBS, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, Baltimore, MD, provides an overview of her talk, which focused on the potential use of immunotherapy for the treatment of patients with myeloproliferative neoplasms (MPNs). Dr Jain mentions some approaches under development, including neutralizing antibodies, bispecific antibodies, and T-regulatory cells (T-reg cells). In addition to this, cellular therapy is being investigated for relapse prevention following stem cell transplantation (SCT). This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Institutional research support from CTI Biopharma, Kartos therapeutics, Incyte, Bristol Myers Squibb, Tscan; Advisory board participation with Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics, Galapagos, Tscan therapeutics, Karyopharm, Morphosys, In8Bio.
